Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttithum, Bruce L. Innis, Saranath Lawpoolsri et al.|medRxiv|2021Cited by 8